Evidence map›Paper›PMID 42884113›Full record

ArticleInternational journal of molecular sciences2026

DENV-2 Genetic Diversity and Variation in Antibody-Dependent Enhancement in Lao PDR.

Dalouny Xayavong, Virasack Somoulay, Bouaphanh Khamphaphongphane, Phonepadith Xangxayarath, Hiromu Osako, Kei Yamasato, Motoki Ihara, Jean Claude Balingit, Mya Myat Ngwe Tun, Kouichi Morita and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dalouny XayavongDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Virasack SomoulayNational Center for Laboratory and Epidemiology, Ministry of Health, Vientiane 01002, Laos.
Bouaphanh KhamphaphongphaneNational Center for Laboratory and Epidemiology, Ministry of Health, Vientiane 01002, Laos.
Phonepadith XangxayarathDepartment of Communicable Diseases Control, Ministry of Health, Vientiane 01002, Laos.
Hiromu OsakoDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Kei YamasatoDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Motoki IharaDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0009-0004-9714-0698
Jean Claude BalingitDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0000-0002-2165-907X
Mya Myat Ngwe TunDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0000-0002-8986-6307
Kouichi MoritaDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0000-0001-8391-1157
Arata HidanoDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0000-0003-1707-5319
Futoshi HasebeGraduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.
Yuki TakamatsuDepartment of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.ORCID 0009-0008-6706-438X

Funding

Heiwa Nakajima Foundation naJapan Agency for Medical Research and Development JP223fa627004, JP24wm0125006, JP24fk0108656, JP24wm0125011, JP24fm0208101Japan Society for the Promotion of Science 24K02288Kurozumi Medical Foundation naMinistry of Education, Culture, Sports, Science and Technology the National BioResource Project (Human Pathogenic Viruses)
6 · The paper itself

Abstract

All four dengue virus serotypes (DENV-1 to DENV-4) can cause severe and potentially fatal disease. Understanding the interplay between host immune responses and viral genetic diversity is particularly crucial in hyperendemic regions, where serotype shifts frequently occur during outbreaks. In this cross-sectional, surveillance-based study, we analyzed 350 patients with confirmed secondary dengue infection in Lao PDR, with samples collected between 2022 and 2023. Of these, 80 were successfully serotyped by RT-PCR and included in the serotype-specific analyses. Viral genotyping was performed using envelope (E) gene sequencing, and neutralizing antibody (nAb) titers and antibody-dependent enhancement (ADE) activities against all four DENV serotypes were assessed using single-round infectious particles in both FcγRIIA-negative and FcγRIIA-positive BHK-21 cells. The nAb titers were highest against DENV-2, followed by DENV-1, DENV-4, and DENV-3. Nevertheless, DENV-2 exhibited the highest ADE activity, suggesting that high nAb titers may not necessarily prevent ADE. We also documented the co-circulation of DENV-2 Cosmopolitan and Asian I genotypes. Our findings highlight the complex interplay between neutralizing and enhancing antibody responses during secondary infection, particularly in the context of DENV-2 infection. Our results emphasize the need to understand the dynamics of DENV transmission in hyperendemic settings and may inform future vaccine development and evaluation strategies.

Indexed as

Antibody-Dependent EnhancementDengueDengue VirusGenetic VariationAnimalsAntibodies, NeutralizingAntibodies, ViralCross-Sectional StudiesGenotypeHumansLaosReceptors, IgGSerogroupViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralReceptors, IgGViral Envelope Proteinsantibody-dependent enhancementdengue virusLao PDRneutralizing antibody

Identifiers

PMID42884113
PMCPMC13664945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.